

14-alpha demethylase inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/1BA03FAA03C5EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: 1BA03FAA03C5EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "14-Alpha Demethylase Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in 14-Alpha Demethylase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

14-Alpha Demethylase Inhibitors Understanding

14-Alpha Demethylase Inhibitors: Overview

Sterol 14alpha-demethylase (CYP51) is the most widely distributed of all members of the cytochrome P450 gene superfamily and the only CYP family found in both prokaryotes and eukaryotes. It is well known as a drug target for microbial pathogenic infections.

Function - The biological role of this protein is also well understood. The demethylated products of the CYP51 reaction are vital intermediates in pathways leading to the formation of cholesterol in humans, ergosterol in fungi, and other types of sterols in

plants. These sterols localize to the plasma membrane of cells, where they play an important structural role in the regulation of membrane fluidity and permeability and also influence the activity of enzymes, ion channels, and other cell components that are embedded within.

14-Alpha Demethylase Inhibitors – These are the compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived antifungal agents act through this mechanism. Azoles are currently the most popular class of antifungals used in both agricultural and medical settings. These compounds bind as the sixth ligand to the heme group in CYP51, thereby altering the structure of the active site and acting as noncompetitive inhibitors. The effectiveness of imidazoles and triazoles (common azole subclasses) as inhibitors of 14 α -demethylase have been confirmed through several experiments.

14-Alpha Demethylase Inhibitors Emerging Drugs Chapters

This segment of the 14-Alpha Demethylase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

14-Alpha Demethylase Inhibitors Emerging Drugs

Oteseconazole: Mycovia Pharmaceuticals

Oteseconazole (VT-1161) is a novel, investigational oral therapy in late-stage clinical development for the treatment of recurrent vulvovaginal candidiasis (RVVC). Oteseconazole is designed with the goal of having greater selectivity, fewer side effects and improved efficacy as compared with currently available antifungal agents. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations. The drug is in preregistration stage for the treatment of Vulvovaginal candidiasis.

Isavuconazonium: Basilea Pharmaceutica

Isavuconazole is an intravenous and oral azole antifungal and the active agent of the

prodrug isavuconazonium sulfate. Isavuconazole is approved in the United States for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis. The drug is currently in phase 3 stage of development for the treatment of Candidiasis.

Further product details are provided in the report.....

14-Alpha Demethylase Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different 14-Alpha Demethylase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on 14-Alpha Demethylase Inhibitors

There are approx. 12+ key companies which are developing the 14-Alpha Demethylase Inhibitors. The companies which have their 14-Alpha Demethylase Inhibitors drug candidates in the most advanced stage, i.e. preregistration include, Mycovia Pharmaceuticals.

Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

14-Alpha Demethylase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

14-Alpha Demethylase Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 14-Alpha Demethylase Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 14-Alpha Demethylase Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence 14-Alpha Demethylase Inhibitors R&D. The therapies under development are focused on novel approaches for 14-Alpha Demethylase Inhibitors.

14-Alpha Demethylase Inhibitors Report Insights

14-Alpha Demethylase Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

14-Alpha Demethylase Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing 14-Alpha Demethylase Inhibitors drugs?

How many 14-Alpha Demethylase Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for 14-Alpha Demethylase Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the 14-Alpha Demethylase Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for 14-Alpha Demethylase Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Mycovia Pharmaceuticals

Basilea Pharmaceutica

Hill Dermaceuticals

Zambon

Pulmocide

Angelini Pharmaceuticals

Biolab Sanus Farmaceutica

Astellas Pharma

Basilea Pharmaceutica

Pulmatrix

Seren Pharmaceuticals

Merck & Co

Laboratoires SMB

ProFem

Key Products

Oteseconazole

Isavuconazonium

Miconazole

ZP 059

PC-945

Benzydamine/econazole

BL-123

BAL 4815

PUR 1900

Fosravuconazole

Posaconazole

ITZ DPI

Prof-001

Contents

Introduction

Executive Summary

14-ALPHA DEMETHYLASE INHIBITORS: OVERVIEW

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

14-ALPHA DEMETHYLASE INHIBITORS – DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

In-depth Commercial Assessment

14-Alpha Demethylase Inhibitors companies' collaborations, Licensing, Acquisition
-Deal Value Trends

14-ALPHA DEMETHYLASE INHIBITORS COLLABORATION DEALS

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Pre-registration)

Comparative Analysis

Oteseconazole: Mycovia Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

PC-945: Pulmocide

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

ZP 059: Zambon

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

14-ALPHA DEMETHYLASE INHIBITORS KEY COMPANIES

14-ALPHA DEMETHYLASE INHIBITORS KEY PRODUCTS

14-ALPHA DEMETHYLASE INHIBITORS- UNMET NEEDS

14-ALPHA DEMETHYLASE INHIBITORS- MARKET DRIVERS AND BARRIERS

**14-ALPHA DEMETHYLASE INHIBITORS- FUTURE PERSPECTIVES AND
CONCLUSION**

14-ALPHA DEMETHYLASE INHIBITORS ANALYST VIEWS

14-ALPHA DEMETHYLASE INHIBITORS KEY COMPANIES

Appendix

I would like to order

Product name: 14-alpha demethylase inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/1BA03FAA03C5EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/1BA03FAA03C5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970